20:08 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Patient sample and mouse studies suggest inhibiting adrenergic receptors , PGR , cortisol receptor GR-2 and/or CHRNB2 could help treat post-stroke...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Mifepristone: Additional Phase I/II data

Data from 13 evaluable patients with glucocorticoid receptor ( GCCR )-positive metastatic triple-negative breast cancer (TNBC) in an open-label, dose-escalation, U.S. Phase I/II trial showed that once-daily 300 mg mifepristone plus 1.1 mg/m 2 Halaven...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Mifepristone: Interim Phase I/II data

Interim data from 13 patients with metastatic breast cancer in the Phase I portion of an open-label, dose-escalation U.S. Phase I/II trial showed that once-daily oral mifepristone plus Halaven eribulin mesylate led to 2 partial...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Mifepristone: Phase III discontinued

Corcept discontinued the double-blind, U.S. Phase III Study 14 after an interim analysis of 226 patients with psychotic depression by an independent DMC showed that once-daily 1,200 mg oral mifepristone was unlikely to meet the...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

Mifepristone: Phase I started

Corcept began an open-label, U.S. Phase I trial to evaluate once-daily oral mifepristone plus IV Halaven eribulin. The first, dose-escalating portion of the trial will enroll up to 20 patients with metastatic breast cancer and...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

Korlym mifepristone: Phase I data

Researchers at the University of Chicago and colleagues reported data from a double-blind, placebo-controlled, U.S. Phase I trial in patients with advanced breast cancer showing that mifepristone plus Abraxane nab-paclitaxel led to a complete or...
07:00 , Aug 13, 2012 |  BioCentury  |  Finance

Cushy deal

Cushy deal...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Corlux mifepristone: Additional Phase III data

Additional data from the subgroup of glucose intolerant patients with endogenous Cushing's syndrome (n=29) in the open-label, U.S. Phase III SEISMIC trial in 50 patients showed that once-daily oral Corlux significantly reduced mean HbA1c from...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

Corlux mifepristone: Additional Phase III data

Corcept Therapeutics Inc. (NASDAQ:CORT), Menlo Park, Calif.   Product: Corlux mifepristone   Business: Other   Molecular target: Progesterone receptor ; Cortisol receptor GR-2   Description: Progesterone and cortisol receptor antagonist   Indication: Treat Cushing's syndrome...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

Corlux mifepristone: Phase III data

Corlux was well tolerated with the majority of serious adverse events determined to be unrelated to treatment. Adverse events related to treatment included symptoms of adrenal insufficiency, endometrial thickening and hypokalemia. The company said 90%...